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Abstract Recent studies demonstrated that the molecules secreted from astrocytes play important roles in the cell
fate determination of neural stem cells (NSCs). However, the exact molecules involved and its possible mechanisms in the process
remain largely unknown. In this study, astrocyte-conditionedmedium (ACM) obtained from astrocytes unstimulated or stimulated
by lipopolysaccharide was prepared to treat NSCs. The results showed that both the proliferation and differentiation of NSCs
treated with stimulated ACMs were significantly increased compared with those treated with unstimulated ACM. Interleukin-6
(IL-6) antibody neutralization of the ACMs decreased NSC proliferation and astrogliogenesis, while NSC neurogenesis was
increased. In contrast, recombinant IL-6 cytokine increasedNSC proliferation and astrogliogenesis, but decreased neurogenesis.
Furthermore, the expression of phosphorylated signal transducer and activator of transcription 3 (p-stat3) protein as well as
serial of basic helix–loop–helix transcription factors (bHLH) mRNA in NSCs exposed to stimulated ACMs significantly increased,
respectively. The expression levels of p-stat3 protein and bHLH mRNA of NSCs were significantly altered after adding anti-IL-6Abbreviations: ACM, astrocyte-conditioned medium; BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; bHLH,
basic helix–loop–helix transcription factors; BMP, bone morphogenetic protein; CNS, central nervous system; CNTF, ciliary neurotrophic
factor; DAPI,4, 6-diamino-2-phenylindole; FBS, fetal bovine serum; GFAP, glial fibrillary acidic protein; IL-1β, interleukin-1 beta; IL-6,
Interleukin-6; JAK/STAT, Janus kinase/signal transducer and activation of transcription; LPS, lipopolysaccharide; MAP2, microtubule-
associated protein 2; MTT, (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; NSCs, neural stem cells; N-ACM, normal ACM; p-
stat3, phosphorylated stat3; TNF-α, tumor necrosis factor-alpha.
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42 F. Wang et al.antibody or recombinant IL-6, respectively. The data suggest that IL-6 secreted fromactivated astrocytes participates in ACM-induced
proliferation and differentiation of NSCs via the phosphorylation of stat3 signals and the expression of bHLH transcription factors.
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Because of the potential of self-renewal and multilineage
differentiation of neural stem cells (NSCs), transplantation of
NSCs has been considered to be a promising therapy for neural
disorders (Blurton-Jones et al., 2009; Wu et al., 2010).
However, some studies have shown that proliferation of the
transplanted NSCs is limited with most of them differentiating
into astrocytes in damaged central nervous system (CNS).
Maintaining the self-renewal capacity of NSCs and controlling
their directeddifferentiation into specific neural cell types are
thereforemajor challenges in using NSCs for neural treatment.
Less clear are the molecular mechanisms that regulate the
proliferation and differentiation of NSCs and how these might
affect the neurogenesis of NSCs under pathologinal conditions.
Recent studies demonstrated that in addition to the intrinsic
properties of stem cells, local microenvironment or “niche”,
such as growth factors, cytokines and cell–cell contact, plays
key roles in the cell fate determination of stem cells (Ma et al.,
2005; Jiao and Chen, 2008; Moyse et al., 2008).
It is well documented that astrocytes constitute a major
component of neural microenvironment in the CNS (Ling and
Leblond, 1973). In addition to providing nutrition, support
and protection to neurons under physiological conditions,
astrocytes play crucial roles in the CNS pathologies. There is
growing evidence that injuries or diseases in the CNS would
not only elicit a characteristic inflammatory reaction but
also enhance proliferation and differentiation of NSCs (Wang
and Shuaib, 2002; Schwab and McGeer, 2008). Astrocytes, as
one of the key players mediating inflammatory response,
were markedly activated in various CNS diseases and
produced pro- and anti-inflammatory cytokines, trophic
factors and chemokines (Ridet et al., 1997; Lau and Yu,
2001), which participated in neuronal survival, maturation
and neurogenesis (Song et al., 2002; Emsley et al., 2004).
This indicates that astrocytes may affect proliferation and
differentiation of NSCs in the injured CNS.
Previous studies have demonstrated that the effects of stem
cell transplantation in animal experiments vary with different
times of cell grafting (Chen et al., 2001; Hofstetter et al.,
2002). One possible explanation for this may be that the tissue
microenvironment at the site of stem cell transplantation
changes along with time after injury and this would cause
different behaviors of transplanted cells. Therefore, unraveling
the molecular signals underlying NSCs and niche interactions
would provide valuable insight into potential usage of NSCs for
neural treatment. Considering the pivotal roles of astrocytes in
neurogenesis (Jiao and Chen, 2008; Song et al., 2002) and our
previous report that molecules secreted from activated
astrocytes during different stages of inflammation affected
bone marrow-derived mesenchymal stem cells in different
manners (Wang et al., 2009), it remains to be elucidated if
molecules derived from astrocytes with distinct inflammatory
states would likewise regulate the cell fate determination of
NSCs.It is well documented that activation of astrocytes and its
related functions in vivo is a complex processwhichmay involve
different stimulating factors. In the present study, astrocytes
were stimulated by lipopolysaccharide (LPS), a potent inflam-
matory activator of astrocytes, tomimic partially the astrocytic
reactions following an inflammatory injury in vivo. NSCs were
then incubated with conditioned medium from LPS-stimulated
astrocytes to determine the effects of inflammation-activated
astrocytes on the proliferation and differentiation of NSCs and
possible molecular signals involved in the process in vitro. The
findings would help explain on how the functional changes of
astrocytes in different phases of CNS diseases or injuries would
affect the stem cells. The study would also provide a cellular
and molecular basis for designing and selecting a proper time
window for an effective NSC transplantation in clinic.Results
Effects of different astrocyte-conditioned mediums
(ACMs) on the proliferation of NSCsTo test the effects of ACMs derived from LPS-activated
astrocytes on the proliferation of NSCs, MTT assay and BrdU
incorporation analysis were performed. The results showed
that both the cell viability andBrdU incorporation ofNSCswere
significantly increased in ACM-treated groups compared with
the DMEM/F12-treated group (Fig. 1). Furthermore, the cell
viability of NSCs was increased in 36 h ACM (0.3318±0.03) and
72 h ACM (0.3103±0.03) groups in comparison with that of
N-ACM (0.2827±0.02) and the difference between N-ACM and
36 h ACM was statistically significant (pb0.05). Similarly, the
BrdU incorporation of NSCs (Fig. 1B,C) was also increased in
36 h ACM (24.17±2.7) and 72 h ACM (21.39±2.9) groups
compared with that of N-ACM (18.26±2.6) and there was
statistically significant difference between N-ACM and 36 h
ACM (pb0.05). Both the results of MTT and BrdU incorporation
assays indicated some mitogenic factors released from LPS-
activated astrocytes could promote NSCs proliferation.
Additionally, the effects of 36 h ACM (pb0.01) and 72 h ACM
(pb0.05) on both NSC viability and BrdU incorporation were
significantly greater than that of 12 h ACM, respectively,
suggesting that themolecules producedby astrocytes varied at
different activated states causing distinct effects on NSCs
proliferation. Because ACM contained LPS, we tested if
residual LPS in ACM would be responsible for the proliferation
and differentiation of NSCs. In this connection, NSCs were
cultured with the same concentration of LPS as ACM. There
was no significant difference between LPS- and DMEM/F12-
treated NSCs (0.2497±0.03 vs 0.2518±0.02) as shown by cell
viability analysis. Similarly, there was also no significant
difference between LPS- and DMEM/F12-treated NSCs in the
BrdU incorporation results (13.74±2.8 vs 13.08±3.1) (Fig. 1),
suggesting that residual LPS does not directly stimulate NSC's
Fig. 1 ACM promotes NSC proliferation. NSCs were cultured in LPS-containing DMEM/F12 (LPS), DMEM/F12 alone, N-ACM, 12 h, 36 h,
and 72 h ACM (without dilution), respectively, with 5 ng/ml bFGF for 2 days and then detected for cell proliferation. A) MTT assay
shows the cell viability. B) Showing the representative BrdU immunofluorescence images in LPS, DMEM/F12, N-ACM, 12 h, 36 h, and
72 h ACM group, respectively. The cell nuclei were counterstained with DAPI. BrdU (red), DAPI (blue). C) Quantification of BrdU-
positive NSCs over the total DAPI-positive cells. Each bar represents mean±SD (n=4). Scale bar: 50 μm. #Pb0.05, ##Pb0.01 vs DMEM/
F12; *Pb0.05 vs N-ACM; ΔPb0.05,Δ Δ pb0.01 vs 12 h ACM.
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et al., 2008; Monje et al., 2003).
Effects of different ACMs on the neuronal
differentiation of NSCs
Previous studies have reported that astrocytes play important
functions in the differentiation of NSCs (Song et al., 2002;
Emsley et al., 2004; Faijerson et al., 2006). To investigate
whether the activated astrocytes at different inflammatory
states havedistinct roles in neurogenesis, NSCswere exposed to
different ACMs for 7 days and then harvested. Immunostaining
andWestern blot were conducted to examine the expression of
MAP2, a specific neuronal marker. Firstly, the results (Fig. 2)
showed that ACM significantly increased the expression ofMAP2
in induced NSCs compared with DMEM/F12 alone. Secondly, as
shown in Fig. 2A,B, the percentage of MAP2-positive cells was
significantly increased in 36 h (31.09±3.1, pb0.01) and 72 h
ACM (27.57±2.9, pb0.05) groups compared with that in N-ACM
group (22.64±2.6). The proportion of MAP2-positive NSCs
exposed to 36 h ACM and 72 h ACM was significantly higherthan that of 12 h ACM (19.35±2.8, pb0.01). This was
corroborated by Western blot results (Fig. 2D) which showed
that MAP2 protein expression in both 36 h and 72 h ACM groups
was more pronounced than N-ACM. MAP2 expression in 12 h
ACM-treated NSCs was the weakest compared with other ACM
groups. In addition, the results showed that compared with
DMEM/F12, the LPS alone did not directly affect NSC's neuronal
differentiation (16.44±2.8 vs 17.18±2.7, pN0.05).
Effects of different ACMs on the astrocytic
differentiation of NSCs
To further explore whether activated astrocytes at different
inflammatory stages regulate the astrogliogenesis differently,
we investigated the expression of GFAP, a specific astrocytic
marker. The results (Fig. 2) also showed that ACMs increased
the expression of GFAP compared with DMEM/F12 alone.
Moreover, as shown in Fig. 2A,C, the percentage of GFAP-
positive cells was increased in NSCs exposed to inflammatory
ACMs (12 h, 36 h and 72 h ACM) comparedwith N-ACM, and the
difference between 36 h (39.78±3.0) or 72 h ACM (37.86±3.1)
Fig. 2 ACM promotes neuronal and astrocytic differentiation of NSCs. Cells were cultured in LPS-containing DMEM/F12 (LPS), DMEM/
F12, N-ACM, 12 h, 36 h, and 72 h ACM, respectively, for 7 days followed by immunostaining with anti-MAP2 and GFAP antibody (green)
and counterstained with DAPI (blue). A) Showing the representative immunofluorescence images of MAP2 and GFAP-positive cells in
different medium groups, respectively. Scale bar: 100 μm. B–C) Quantitative analysis of MAP2 (B) and GFAP (C)-positive cells over the
total DAPI cells. Data are presented as mean±SD (n=5). D–E) Western blotting results show the expression level of MAP2 (D) and GFAP
(E) protein in NSCs induced by different ACMs. β-actin serves as an internal control. #Pb0.05, ##Pb0.01 vs DMEM/F12; Δ Pb0.05, Δ Δ
pb0.01 vs N-ACM; *Pb0.01 vs 12 h ACM; §Pb0.05 vs 12 h ACM.
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The frequency of GFAP-positive NSCs in 36 h ACM group was
significantly higher than that of 12 h ACM (34.17±2.9,
pb0.05). Western blot results (Fig. 2E) showed that GFAP
protein expression in 12 h, 36 h and 72 h ACM groups was
stronger than N-ACM, respectively, and GFAP expression in
36 h ACM group was the highest among different inflammatory
ACM groups. Besides, there was also no significant difference
on NSC's astrocytic differentiation between LPS- and DMEM/F12-treated NSCs (26.45±2.7 vs 25.37±2.8)(Cacci et al., 2008;
Monje et al., 2003).Bioactive molecules secreted from the astrocyte
cultures
The foregoing data implicated that molecules produced by
activated astrocytes can modulate the fate specification of
45Roles of astrocyte in stem cell proliferation and differentiationneural stemcells. Todetermine thepossible factors inACM that
contribute to NSC proliferation and differentiation,
proinflammatory cytokines interleukin-6 (IL-6), tumor necrosis
factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) and trophic
factor brain-derived neurotrophic factor (BDNF) were
quantified in ACMs by ELISA. As shown in Fig. 3, the levels of
IL-6, IL-1β, TNF-α and BDNF expression were all strongly
elevated in inflammatory ACMs collected from LPS-stimulated
astrocytes compared with N-ACM (pb0.01). Moreover, the
amount of IL-6 in36 hACM(1745±213)was significantly greater
than that in 12 h ACM (1256±187, pb0.05, Fig. 3A). In addition,
the amount of TNF-α in 36 h ACM (1254±221) was significantly
greater than that in 72 h ACM (736±186, pb0.05, Fig. 3B).
Besides, the expression of IL-1β in both 36 h ACM (1752±221)
and 72 h ACM (1822±213) was significantly greater than that in
12 h ACM (390±45, pb0.01, Fig. 3C). However, there was no
significant difference in the production of BDNF in different
inflammatory ACMs (12 h, 36 h, and 72 h ACMs) (Fig. 3D).IL-6 participates in ACM-induced proliferation of
NSCs
It has been reported that IL-6 expression is significantly
increased in various CNS disorders and plays pleiotropic
functions during the processes (Acalovschi et al., 2003;
Nakamura et al., 2005). Remarkably, the pattern changes of
IL-6 expression in different ACMs as described earlier appear to
coincide with the effects of different ACMs on the NSCs,
suggesting that the cytokine may contribute to the prolifer-
ation and differentiation of NSCs exposed to different ACMs.
Furthermore, some previous results have shown the
contradictory effects of IL-6 on the behaviors of NSCs (Monje
et al., 2003; Barkho et al., 2006). To elucidate the roles of IL-6
on NSCs, we examined the effects of IL-6 in different ACMs on
NSCs. Exogenous anti-IL-6 antibody and recombinant IL-6Fig. 3 Analysis of proinflammatory cytokines IL-6, TNF-α, and IL-1
amounts of serial molecules such as IL-6 (A), TNF-α (B), IL-1β (C) and
stimulated by LPS for 12 h, 36 h or 72 h, respectively. Each bar repres
▴pb0.01,vs 72 h ACM.cytokine were added into different ACMs 1 h prior to their use
for NSC treatment. The dose of IL-6 and IL-6 antibody was first
determined by the concentration gradients which showed that
recombinant IL-6 cytokine at 50 ng/ml and IL-6 antibody at
30 ng/ml was optimal (data not shown). The effects of
astrocyte-derived IL-6 on the proliferation of NSCs were then
investigated. As shown in Fig. 4, following neutralization of IL-
6with anti-IL-6 antibody, the percentageof BrdU-positive cells
was reduced comparedwith the corresponding control (except
for 12 h ACM). The reduction was statistically significant in
36 h (24.83±2.5 vs 20.77±2.3) and 72 h (22.67±2.6 vs 18.56±
2.3) ACM group (pb0.05). In contrast, addition of recombinant
IL-6 cytokine significantly increased the proportion of BrdU-
positive cells in NSCs compared with DMEM/F12 medium alone
(12.58±2.4 vs 16.41±2.3, pb0.05).IL-6 inhibits the neurogenesis of NSCs induced by
ACM
Several in vitro studies havedemonstrated that IL-6participates
in modulating the differentiation of NSCs (Monje et al., 2003;
Taga and Fukuda, 2005; Islam et al., 2009). To investigate
whether IL-6 secreted fromLPS-activated astrocytes affects the
neuronal differentiation of ACMs-treated NSCs, anti-IL-6
antibody or recombinant IL-6 cytokine was added into different
media. The differentiation of NSCs was examined by
immunocytochemistry and Western blotting methods. Results
of immunostaining analysis (Fig. 5A) showed that neutralization
of IL-6 with anti-IL-6 antibody increased ACM-induced neuronal
differentiation of NSCs in different ACMs. The increase both in
36 h (30.49±2.6 vs 35.41±2.5) and 72 h (27.07±2.5 vs
31.75±2.4) ACM groups was statistically significant compared
with the corresponding control, respectively (pb0.05). In
contrast, after adding recombinant IL-6 cytokine into the
DMEM/F12 medium, the percentage of MAP2-positive NSCs wasβ, and trophic factor BDNF expression. Results of ELISA show the
BDNF (D) collected from DMEM/F12 or astrocytes unstimulated or
ents mean±SD (n=3). *pb0.01, vs N-ACM; Δ pb0.01,vs 12 h ACM;
Fig. 4 IL-6 affects ACM-induced proliferation of NSCs. NSCs
were cultured in N-ACM, 12 h, 36 h, and 72 h ACM, respectively,
in the presence of anti-IL-6 antibody or the lack of it (control).
Along with this, NSCs were cultured in DMEM/F12 medium with
IL-6 cytokine. After treatment for 2 days, the NSCs were
incubated with BrdU for 6 h. Quantitative analysis of BrdU-
positive NSCs shows the proliferation changes of NSCs after IL-6
antibody neutralization or adding IL-6. Data are presented as
mean±SD (n=5). *pb0.05.
Fig. 5 IL-6 affects ACM-induced neuronal and astrocytic differentia
respectively, with 1% FBS in the presence of anti-IL-6 antibody or th
medium with 1% FBS in the presence of IL-6 cytokine. After treatmen
and analyses. A,D) Quantification of immunostaining analysis shows t
cells in NSCs after neutralization or addition of IL-6. B,E) Western bl
different ACM-induced NSCs. β-actin serves as the internal control. C
(F) in NSCs shows the changes of neuronal and astrocytic different
**pb0.01.
46 F. Wang et al.significantly decreased (17.14±2.4 vs 13.16±2.3, pb0.05). The
results of immunocytochemistry were consistent with Western
blot analysis (Fig. 5B,C) which showed that the protein
expression of MAP2 in both 36 h (0.88±0.07 vs 1.07±0.08) and
72 h (0.74±0.08 vs 0.91±0.07) ACM groups was significantly
stronger than the corresponding control, respectively (pb0.05).
The MAP2 level was significantly reduced after NSCs were
treated with recombinant IL-6 (0.34±0.06 vs 0.21±0.05,
pb0.05). Moreover, addition of exogenous IL-6 cytokine into
the 36 h ACM significantly reduced the percentage of MAP2
positive cells (29.76±2.5 vs 25.16±2.4, pb0.05).
IL-6 promotes the astrogliogenesis of NSCs induced
by ACM
To further confirm whether IL-6 is involved in the astrocytic
differentiation of ACM-induced NSCs, we examined the
expression of GFAP in these cells. As shown in Fig. 5D, IL-6
antibody neutralization reduced the astrocytic differentiation
of ACM-inducedNSCs. The reductionwas statistically significant
between 12 h (33.95±2.6 vs 28.69±2.4), 36 h (39.87±2.5 vs
34.64±2.7) or 72 h (37.76±2.6 vs 32.27±2.5) ACM and thetion of NSCs. NSCs were cultured in N-ACM, 12 h, 36 h, 72 h ACM,
e lack of it. In parallel to this, NSCs were cultured in DMEM/F12
t for 7 days, the NSCs were processed for different experiments
he changes of MAP2(A) and GFAP(D)-positive cells over the total
ot shows the expression level of MAP2(B) and GFAP(E) protein in
,F) Quantification of the protein expression of MAP2 (C) and GFAP
iation of NSCs. Each bar represents mean±SD (n=5). *pb0.05,
Fig. 6 Stat3 is involved in IL-6-induced proliferation of NSCs
exposed to ACMs. NSCs were cultured in N-ACM, 12 h, 36 h, 72 h
ACM, respectively, with 5 ng/ml bFGF in the presence or
absence (control) of anti-IL-6 antibody. Meanwhile, NSCs were
cultured in DMEM/F12 medium with 5 ng/ml bFGF in the
presence of IL-6. A) Western blot shows the protein expression
of p-stat3 (tyr705) and total stat3 in NSCs exposed to different
media. β-actin serves as the internal control. B) Quantitative
analysis of expression level of p-stat3 (tyr705) in NSCs shows the
expression changes of p-stat3 (tyr705) in NSCs. Data are
presented as mean±SD (n=4). *pb0.05, **pb0.01.
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addition of recombinant IL-6 cytokine significantly increased
GFAP-positive cells in NSCs (24.23±2.4 vs 31.04±2.6, Pb0.01).
Moreover, Western blot analysis (Fig. 5E,F) showed that the
protein expression of GFAP was decreased after IL-6
neutralization in different ACMs [12 h (0.86±0.07 vs 0.67
±0.08), 36 h (1.04±0.06 vs 0.87±0.04), 72 h ACM (0.97±0.05 vs
0.81±0.06, Pb0.05]. GFAP expression was significantly in-
creased after adding recombinant IL-6 into the DMEM/F12
medium (0.53±0.06 vs 0.79±0.05, Pb0.01). Besides, addition
of IL-6 cytokine into the 36 h ACM also significantly increased
the percentage of GFAP positive cells (39.46±2.3 vs 44.57±2.4,
pb0.05).
Stat3 signal participates in IL-6-induced
proliferation of NSCs treated with ACMs
It has been reported that Janus-activated kinase/signal
transducer and activation of transcription 3 (JAK/Stat3)
signaling pathway plays crucial roles in the fate determination
of NSCs (Gu et al., 2005; Cao et al., 2010). In light of this, we
investigated whether Stat3 is involved in ACM-induced cell
proliferation and differentiation of NSCs. As depicted in Fig. 6,
ACMs induced the phosphorylation of an 80-kDa protein
specifically recognizedbyanti-phospho-Stat3 (p-Stat3) antibody
during NSCs proliferation. The expression of p-Stat3 (tyr705) in
NSCs exposed to 12 h, 36 h, 72 h ACMwas significantly enhanced
compared with N-ACM, respectively. However, the total Stat3
protein expression of NSCs appeared to be unaltered when
exposed to different ACMs. To further ascertain the function of
Stat3 in ACM-induced NSCs proliferation, anti-IL-6 antibody or
recombinant IL-6 cytokine was added into the different media,
respectively. The results showed that compared with the
corresponding control, the protein level of p-Stat3 (tyr705)
was significantly increased after adding recombinant IL-6
cytokine (0.17±0.05 vs 0.33±0.04, Pb0.05), while its expres-
sion was decreased after adding the IL-6 antibody, especially in
12 h (0.42±0.05 vs 0.30±0.04,), 36 h (0.43±0.06 vs 0.31±0.04,)
and 72 h (0.46±0.05 vs 0.35±0.03) ACM groups, and the
reduction is statistically significant, respectively (Pb0.05).
Furthermore, results about the expression change of p-Stat3
(tyr705) were also obtained during NSC differentiation (data not
shown). The aforementioned data support that Stat3 is involved
in NSC proliferation and differentiation induced by astrocyte-
derived IL-6.
bHLH transcription factors participate in IL-6-
induced differentiation of NSCs treated with ACMs
It is well documented the basic helix–loop–helix transcription
factors (bHLH) are highly expressed by NSCs and positively or
negatively regulate the neurogenesis and astrogliogenesis
(Kageyama et al., 2005; Cao et al., 2006). To determine
whether bHLH transcription factors are involved in the
differentiation of ACM-induced NSCs, RT-PCR analyses were
conducted to examine mRNA levels of proneuronal bHLH
transcription factors (Mash1 and Neurog1) and inhibitory bHLH
transcription factors (Hes5andHes1) in differentiatedNSCs. The
results (Fig. 7) showed that following IL-6 neutralization, mRNA
levels of Mash1 and Neurog1 increased. The increase in Mash1
mRNA expression (Fig. 7A,B) was statistically significant in 12 h(0.41±0.03 vs 0.52±0.05), 36 h (0.50±0.06 vs 0.64±0.04) and
72 h (0.47±0.05 vs 0.58±0.03) ACM groups compared with the
corresponding control, respectively (Pb0.05). Similarly,
Neurog1 mRNA levels (Fig. 7D,E) were significantly increased
after IL-6 neutralization in 36 h (0.48±0.05 vs 0.61±0.04) and
72 h (0.45±0.03 vs 0.55±0.04) ACM groups compared with the
corresponding control, respectively (Pb0.05). However, the
anti-IL-6 antiserum significantly reduced the mRNA expression
of Hes5 (Fig. 7A,C) and the difference between 12 h (0.47±0.05
vs 0.37±0.04), 36 h (0.54±0.06 vs 0.43±0.04) and 72 h
(0.50±0.05 vs 0.40±0.03) ACM group and the corresponding
control was statistically significant, respectively (pb0.05).
Contrary to anti-IL-6 antiserum, recombinant IL-6 cytokine
significantly increased the mRNA expression level of Hes5
(0.28±0.05 vs 0.37±0.04, pb0.05), while reduced the mRNA
expression of Mash1 (0.24±0.05 vs 0.14±0.04) and Neurog1
(0.27±0.03 vs 0.15±0.03), respectively (pb0.05). Interestingly,
IL-6 neutralization or IL-6 cytokine did not significantly affect
the expression of Hes1 mRNA (Fig. 7D,F). The data suggest that
enhanced or reduced expression of these transcription factors
may contribute to the increased or decreased neurogenesis and
astrogliogenesis caused by astrocyte-derived IL-6.
Discussion
This study investigated the effects of inflammation-activated
astrocytes at different stages on the proliferation and
differentiation of NSCs as well as the possible molecular
mechanisms involved in the processes. We showed that
inflammatory ACMs promoted the proliferation and
differentiation of NSCs, notably the 36 h ACM which exerted
a greater effect on NSCs than other ACMs. Moreover, we
Fig. 7 bHLH transcription factors participate in IL-6-induced neural differentiation of NSCs exposed to ACMs. The NSCs were
cultured in N-ACM, 12 h, 36 h, 72 h ACM, respectively, with 1% FBS in the presence or absence (control) of anti-IL-6 antibody.
Meanwhile, NSCs were cultured in DMEM/F12 medium with 1% FBS in the presence of IL-6. RT-PCR analyses show the mRNA expression
levels of bHLH transcription factors, Mash1 Neurog1, Hes5 and Hes1. β-actin serves as the internal control. Values are presented as
mean±SD from four independent measurements. *pb0.05.
48 F. Wang et al.identified astrocyte-derived IL-6 as a molecule important for
ACM-induced proliferation and differentiation via the
phosphorylation of Stat3 signaling pathway. In addition, the
bHLH transcription factors such as Mash1, Neurog1 and Hes5
also participate in the ACM-induced NSCs differentiation.
Accumulating evidence has demonstrated that astrocytes
play important roles in modulating the proliferation and
differentiation of NSCs (Ma et al., 2005; Song et al., 2002)
However, little is known on how activated astrocytes under
inflammatory CNS circumstances regulate the behavior of NSCs.The present results have shown that compared with N-ACM,
36 h and 72 h ACM significantly promoted proliferation and
differentiation of NSCs (Figs. 1 and 2), suggesting that
inflammation-activated astrocytes exerted greater effects in
cell fate determination of NSCs than unstimulated astrocytes. It
has been reported that in response to stimulation, astrocytes
significantly upregulate the production of a plethora of
molecules, including pro- and anti-inflammatory cytokines,
growth factors and trophic factors (Ridet et al., 1997;
Lieberman et al., 1989; Lafon-Cazal et al., 2003; Vesce et al.,
49Roles of astrocyte in stem cell proliferation and differentiation2007).Most of the secreted factors, such as IL-6, TNF-α, retinoic
acid, nerve growth factor and ciliary neurotrophic factor
(CNTF), have been demonstrated to participate in the
proliferation and differentiation of NSCs (Ma et al., 2005;
Cattaneo and McKay, 1990; Bonni et al., 1997; Ricci-Vitiani et
al., 2006; Környei et al., 2007; Johansson et al., 2008). It would
appear therefore that the increased factors from activated
astrocytes in combination might form a special stem cell
microenvironment that may facilitate the proliferation and
differentiation of NSCs. Horner and others have reported that
astrocytes activated by ischemia or mechanical-lesion
significantly accelerate the proliferation and differentiation
of neural stem/progenitor cells (Faijerson et al., 2006; Horner
and Palmer, 2003). Taken together, it is suggested that
optimally activated astrocytes under inflammatory CNS condi-
tionsmaypromote theproliferation anddifferentiation ofNSCs.
The present study has extended our previous observations
(Wang et al., 2009) that ACMs derived from astrocytes
stimulated by LPS for different duration exerted distinct roles
on NSCs. Previous studies showed that the factors produced by
activated astrocytes varied considerably with the nature,
intensity and persistence of stimulation (Tokumine et al.,
2003). It was reported that different molecules or the same
factors but of different concentrations would have distinct
effects on the behavior of stem cells. For example, Chang et al.
(2003) reported that theeffects of bonemorphogeneticprotein
(BMP) on NSCs are dose-dependent, namely, low doses of BMP
stimulated cortical NSCs to exclusively differentiate into
neurons, while astrocyte differentiation was induced when
higher doses of BMPs were used. Besides, CNTF and other
molecules with different concentrations were also reported to
have distinct effects on the fate specification of NSCs (Qian et
al., 1997; Bhattacharya et al., 2008). Considering the pivotal
effects of local microenvironment on stem cells (Ma et al.,
2005; Ricci-Vitiani et al., 2006; Constantinescu, 2000; Temple,
2001), it is suggested that activatedastrocytes at various stages
may have distinct roles in regulating the behavior of stem cells
by releasing different factors. This should be taken into
consideration in designing and selection of time point for an
effective NSC transplantation therapy.
It has been reported that the bioactive molecules produced
by astrocytes participate in regulating the behavior of NSCs (Ma
et al., 2005; Song et al., 2002). Our results have shown that
several proinflammatory cytokines including IL-6, TNF-α and
IL-1β, and trophic factor BDNF are secreted from stimulated
and unstimulated astrocytes (Fig. 3). Identification of the
molecular cues thatmodulateNSCs fate choice is a prerequisite
for their therapeutic applications. Among the various
molecules, IL-6, a pleiotropic inflammatory factor, was
systematically investigated in the present study. This takes
into account of the vigorous activation of astrocytes in the
damaged CNS and the fact that IL-6 expression is significantly
increased in various CNS disorders and that it participates in
the proliferation and differentiation of stem cells (Acalovschi
et al., 2003; Nakamura et al., 2005; Taga and Fukuda, 2005). In
the present study, ELISA results have shown that IL-6
expression was significantly up-regulated in inflammatory
ACMs from activated astrocytes and the amounts of IL-6
secreted in 12 h, 36 h and 72 h ACM varied according to the
duration of LPS stimulation. The varied expression changes of
IL-6 suggest that the cytokine may contribute to the
proliferation and differentiation of varying magnitude in NSCsexposed to different ACMs. This notion lends its support from
the fact that NSCs changed their behaviors swiftly with IL-6
antibody neutralization or exogenous application of IL-6 in the
medium. This is in agreement with earlier studies which
reported that IL-6 participates in modulating the proliferation
and differentiation of NSCs (Taga and Fukuda, 2005; Islam et
al., 2009). Vallières et al. reported that hippocampal
neurogenesis was significantly reduced in adult transgenic
micewith chronic astrocytic production of IL-6 (Vallières et al.,
2002). Additionally, it has been reported that astrocytic
differentiation of NSCs was apparently decreased with the
blockade of the action of IL-6 receptor (Okada et al., 2004). In
addition to modulating the differentiation of NSCs, IL-6 is also
reported to be involved in NSC proliferation (Kang and Kang,
2007). In consideration of our present results along with others
(Wanget al., 2009; Barkho et al., 2006), it is suggested that IL-6
serves as an importantmolecule in regulating the ACM-induced
proliferation and differentiation of NSCs. Further studies using
IL-6 gene knockout mice or injecting IL-6 cytokine or IL-6
antibody in vivo may allow us to decipher the role of IL-6 in
response to various CNS diseases.
Previous studies have reported that IL-6 binds to the
heterodimeric complex gp130/IL-6 receptors, followed by
the activation of JAK/STAT pathway (Gu et al., 2005;
Heinrich et al., 1998; Bauer, 2009). The activated Stat3
then translocates into the nucleus, regulates the expression
of different transcription factors and plays various biological
effects, such as cell survival, apoptosis, proliferation,
migration and differentiation (Gu et al., 2005; Kang and
Kang, 2007; Schindler and Darnell, 1995; Ihle, 2001; Iwamaru
et al., 2007). Recently, there is increasing evidence that
JAK/STAT signaling pathway plays crucial roles in the
determination of the fate of NSCs. For instance, some
studies have reported that inhibition of Stat3 activity
suppresses astrogliogenesis and promotes neurogenesis in
cultured NSCs (Gu et al., 2005; Cao et al., 2006). The present
results have shown that the expression of p-stat3 was
apparently increased in NSCs induced by inflammatory
ACMs during NSC proliferation. More importantly, the
expression was significantly changed with the neutralization
of IL-6 or with the addition of exogenous IL-6 cytokine,
respectively. Besides, the expression of p-Stat3 during NSC
differentiation is similar to that during NSC proliferation in
our culture conditons (data not shown), which is consistent
with previous reports that JAK/STAT3 participated in the
differentiation of NSCs (Gu et al., 2005; Cao et al., 2010;
Bonni et al., 1997). Arising from this, it is suggested that IL-6
modulates the ACM-induced proliferation and differentiation
of NSCs via the phosphorylation of Stat3 signaling at least.
Despite the many studies in recent years on neurogenesis
and gliogenesis, the precise mechanisms by which they are
regulated in the NSCs remain to be elucidated. In addition to
the JAK/STAT3 signaling pathway we discussed earlier,
accumulating data have shown that the bHLH transcription
factors, play important roles in the determination of neuron
and glia cell fates from NSCs during fetal and adult brain
development (Kageyamaet al., 2005; Ross et al., 2003; Havrda
et al., 2008). Several studies have shown that the proneural
bHLH transcription factors such as Mash1, Neurog1, and
NeuroD2 participate in the vertebrate neurogenesis and
increase in Mash1 and Neurog1 expression leads to the
initiation of neurogenesis. On the other hand, upregulated
50 F. Wang et al.expression of inhibitory transcription factors Hes and Id
increased astrogliogenesis (Nakamura et al., 2001; Ito et al.,
2003; Sugimori et al., 2007). We show here the involvement of
Mash1, Neurog1 and Hes5 in the ACM-induced neuronal and
astrocytic differentiation of NSCs. In this connection, ACMs
markedly induced upregulation of Mash1, Neurog1 and Hes5
mRNA in differentiated NSCs. In addition, exogeneous
application of IL-6 antibody or recombinant IL-6 cytokine
significantly affected the mRNA expression levels of the
transcription factors, suggesting that the neurogenesis or
astroglionenesis of NSCs caused by ACMs is partially attributed
to the expression of these transcription factors. However, in
the present study, there was no significant expression change
in Hes1 mRNA when the NSCs were exposed to different ACMs,
and IL-6 neutralization or addition of IL-6 cytokine did not also
significantly affect the expression of Hes1 mRNA, suggesting
that Hes1 may not participate in IL-6-induced differentiation
of NSCs treated with ACMs.
Although IL-6 in the ACMs participates in the proliferation
and differention of NSCs as shown in the present study, it needs
to be emphasized that IL-6 neutralization did not completely
block ACM-induced NSC proliferation and differentiation
compared with DMEM/F12 medium alone. This suggests that
apart from IL-6, other molecules secreted by activated
astrocytes may be involved in the process. As shown in Fig. 3,
the production of other proinflammatory cytokines such as
TNF-α and IL-1β, and trophic factor BDNF from astrocytes has
also increased significantly. Furthermore, consistent with the
findings by others (Liu et al., 2005; Peng et al., 2008), TNF-α
participates in the proliferation and differentiation of NSCs
(data not shown). In addition, BDNF, IL-1β, BMP, CNTF, nerve
growth factor; and retinoic acid derived from astrocytes were
also confirmed to participate in modulating the fate
determination of NSCs (Cattaneo and McKay, 1990; Környei et
al., 2007; Chang et al., 2003; Nakanishi et al., 2007). All these
indicate that IL-6 along with other molecules derived from
astrocytes may act in concert either to facilitate or inhibit the
behaviors of NSCs. The combined actions of these bioactive
molecules on NSCs are very complex and await further
exploration both in vitro and in vivo.
Materials and methods
The International Guiding Principles for Animal Research,
as stipulated by the World Health Organization (1985)
(Howard-Jones, 1985) and as adopted by the Laboratory
Animal Center, Shandong University were followed. All efforts
were made to reduce the number of mice and their suffering.
Astrocyte culture and preparation of conditioned
medium
Primary astrocytes were prepared from 1-day-old KunMing
mice as described before (McCarthy and de Vellis, 1980) with
modifications. Briefly, the cell suspension of cortical tissues
freed of meninges and blood vessels was seeded in DMEM/F12
medium (Hyclone, USA) supplemented with 10% fetal bovine
serum (FBS, Hyclone, USA). After incubating for 10 days, to
obtain pure astrocytes, the primary mixed cells were orbitally
shaken at 200 rpm for 6 h and the supernatant was removed.
The attached cells in the plate were washed with phosphate-buffered saline, digested by trypsin and then replated. The
purity of the cultures was assessed by indirect immunofluo-
rescence for the astrocytic specific marker (glial fibrillary
acidic protein, GFAP, Chemicon). On average, 96.2±0.6% of
the cells were positive for the expression of GFAP. When the
astrocytes have reached about 80% of confluence at passage 3,
the cells were treated with fresh DMEM/F12 plus 1 μg/ml LPS
(from Escherichia Coli, serotype 026:B6, Sigma-Aldrich, USA)
for 12, 36 and 72 h, respectively. After stimulation, the
supernatant was collected, respectively, to obtain the
inflammatory astrocyte-conditioned medium (ACM) at the
foregoing time points designated as 12 h ACM, 36 h ACM and
72 hACM.Meanwhile, the supernatant fromastrocytes treated
with fresh DMEM/F12 alone for 36 hwas collected to be used as
normal ACM (N-ACM). The ACMs were centrifuged, filtered and
stored at −80 °C until tested or later use.
Neural stem cell cultures
The primary culture of NSCs was prepared from embryos
(E13.5) of KunMing mice as described previously (Fu et al.,
2006). Briefly, the telencephalon was dissected out from the
embryo and the cultures were incubated in the growth
medium consisting of DMEM/F12 supplemented with basic
fibroblast growth factor (bFGF) (20 ng/ml, Gibco Invitrogen
Corporation), epidermal growth factor (20 ng/ml, Gibco
Invitrogen Corporation) and 2% B27 (Gibco Invitrogen
Corporation) (growth medium). The culture medium was
changed every 2 days and the cells grew into floating
neurospheres. After 7 days in vitro, primary neurospheres
were dissociated into single cells and the cells grew into
neurospheres again. Secondary or tertiary neurospheres
were used for subsequent experiments and all experimental
procedures were carried out using monolayers of NSCs.
Neural stem cells viability analysis
Cell viability of NSCs was determined by the tetrazolium salt
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium
bromide) assay. Dissociated NSCs were seeded at a density of
5×103 cells/ml in poly-L-lysine (Sigma-Aldrich,USA)-coated 96-
well culture plate and cultured in NSC growthmedium for 24 h.
NSCswere thenexposed toN-ACM, 12 h ACM, 36 h ACMand 72 h
ACM (without dilution), respectively, with 5 ng/ml of bFGF.
After 48 h of incubation, MTT solution (5 mg/ml) was added to
each well and incubated at 37 °C for 4 h. The medium was
gently aspirated and 200 μl dimethylsulfoxide was added to
each well. The optical density of each sample was immediately
measured in a multiwell spectrophotometer (BioRad, USA) at
490 nm. Separate experiments were conducted four times.
Proliferation index by bromodeoxyuridine (BrdU)
labeling and immunostaining
To examine the proliferation, dissociated NSCs were plated
on coverslips pre-coated with poly-L-lysine in six-well plates
and cultured in NSC growth medium for 24 h. Then, the NSCs
were treated with N-ACM, 12 h ACM, 36 h ACM and 72 h ACM
(without dilution), respectively, with 5 ng/ml of bFGF for
2 days in the absence or presence of 30 ng/ml anti-IL-6
antibody (Chemicon, USA). In addition, NSCs were exposed to
Table 1 Sequences and PCR product sizes for each pair of
probes.
Primer Sequence (5′→3′) Product
size (bp)
Mash1 F:AAG TCA GCG GCC AAG CAG GTC AAG 245
R:CGC AGC GTC TCC ACC TTG CTC ATC T
Neurog1 F:CGA TCC CCT TTT CTC CTT TC 239
R:TGC AGC AAC CTA ACA AGT GG
Hes5 F:GAT GCT CAG TCC CAA GGA GA 236
R:CGC TGG AAG TGG TAA AGC AG
Hes1 F:CGA GCG TGT TGG GGA AGT A 101
R:AGT GCG CAC CTC GGT GTT A
β-actin F:AGA TGT GGA TCA GCA AGC AG 104
R:GCG CAA GTT AGG TTT TGT CA
F, forward; R, reverse.
51Roles of astrocyte in stem cell proliferation and differentiationDMEM/F12 midium with 5 ng/ml of bFGF for 2 days with or
without recombinant 50 ng/ml IL-6 cytokine (RD, USA). BrdU
(10 μg/ml, Sigma-Aldrich) was then added to each medium
for 6 h and the cell proliferation activity was estimated by
BrdU incorporation analysis through immunocytochemistry.
Cells were fixed in 4% paraformaldehyde for 20 min, treated
with 2 mol/L HCl at 37 °C for 30 min, blocked with 5% normal
goat serum for 30 min, and incubated with anti-BrdU
monoclonal antibody (1:1000, Sigma-Aldrich) overnight at
4 °C. Anti-mouse IgG coupled to TRITC (1:200, Chemicon,
USA) was used as the secondary antibody. Then the cells
were counterstained by 4, 6-diamino-2-phenylindole (DAPI,
Sigma-Aldrich, USA). The percentage of BrdU-positive cells
over total DAPI cells was determined by randomly counting
10 nonoverlapping microscopy fields of three coverslips for
each condition, in at least four independent experiments. An
average of 100 cells per field was counted.
Neural differentiation of NSCs
Dissociated NSCs were plated on coverslips pre-coated with
poly-L-lysine in six-well plates and cultured in NSC growth
medium for 24 h. Following this, the NSCs were treated with
N-ACM, 12 h ACM, 36 h ACM and 72 h ACM (without dilution),
respectively,with1%FBS in theabsenceorpresenceof 30 ng/ml
anti-IL-6 antibody. Along with this, NSCs were exposed to
DMEM/F12 medium with 1% FBS with or without recombinant
50 ng/ml IL-6 cytokine. The media were changed every 2 days.
After 7 days of induction, the cellswere collected andprocessed
for immunostaining and Western blotting analysis.
Immunofluorescence assay
The induced cellswere fixedwith 4%paraformaldehyde in PBS,
permeabilized with 0.3% Triton X-100, and blocked with 5%
normal goat serum. Then the cells were incubated with
primary antibodies that mark microtubule-associated protein
2 (MAP2) (1:200, monoclonal, Chemicon), and GFAP (1:500,
monoclonal, Chemicon) overnight at 4 °C. Subsequently, cells
were incubated with FITC-conjugated secondary antibodies
and counterstained with DAPI. Labelled cells were visualized
and photographed with a fluorescence microscope (IX71,
Olympus, Japan). Immunoreactivity was abrogated when the
primary antibodieswere omitted from the incubationmedium.
The percentage of neuron- and astrocyte-positive cells in
relation to the total cells was determined in 10 independent
fields for each condition in five separate experiments. An
average of 100 cells per field was counted.
Western blots analysis
The induced cells were lysed and centrifuged at 14,000×g for
20 min. Protein concentration of the supernatants of cell
extract was determined using a BCA protein assay kit (Pierce
Biotechnology Inc, USA). Equivalent amounts of protein
samples were loaded on SDS-polyacrylamide gel. After
electrophoresis, the proteins were transferred to PVDF
membranes, and the blots were subsequently probed with
the following antibodies: MAP2 (1:1000), GFAP (1:1000), stat3,
p-stat3) (1:1000, CST), and β-actin (1:1000, Sigma-Aldrich).
For detection, horseradish peroxidase-conjugated secondaryantibodies were used (1:5000) followed by enhanced
chemiluminescence development (Millipore). Normalization
of the results was done by running parallel Western blots using
β-actin as control. The optical densitywas quantified using the
Image-Pro Plus 6.0 software. Separate experiments were
conducted four times.
Enzyme linked immuno sorbent assay (ELISA)
To identify the activation of astrocytes and explore the
amounts of cytokines in different ACMs, enzyme linked immuno
sorbent assay (ELISA) was adopted. The amount of proinflam-
matory cytokines IL-6, TNF-α, IL-1β and trophic factor BDNF in
different ACMs was measured using ELISA assay, respectively
(IL-6 and IL-1β kits were purchased from Genetimes, China;
TNF-α and BDNF kits were purchased from R&D, USA). The
procedures were strictly carried out according to the descrip-
tion of the ELISA kits and the optical density (OD)wasmeasured
at 450 nm in a standardmicroplate reader (BioRad, USA). Three
independent experiments were conducted.
Reverse transcription-polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from NSC cultures using the Trizol
(Invitrogen) method. RNA concentration was determined by a
spectrophotometer at 260 nm. Identical amounts of RNA were
reverse transcribed into cDNA, which was subsequently
amplified by PCR with specific primers. Primers for detecting
genes are listed in Table 1. The PCR products separated on
1.5% agarose/TAE gels were visualized by staining with
ethidium bromide and semiquantified using AlphaEase FC
Version 4 analysis software (Alphalmager HP, Alpha Innotech,
USA). The densitometric analysis of the datawas normalized to
the β-actin. Results were mean±SD from four separate
experiments for each group.Statistical analysis
All data were presented as mean±SD of at least three
independent experiments. Statistical analysis of data was
52 F. Wang et al.made by Student's t-test or one-way analysis of variance
(ANOVA) followed by Dunnett's multiple comparison test.
Pb0.05 was considered to be statistically significant.
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